Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Myeloid 2Lymphoid 2Genitourinary 2Gastrointestinal 2CNS 2

Conditions

Pancreatic Neoplasms 4Glioma 4Melanoma 3Colorectal Neoplasms 3Wilms Tumor 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Stomach Neoplasms 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Ovarian Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasms 2Multiple Myeloma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Gastrointestinal Neoplasms 2Esophageal Neoplasms 2Ependymoma 2Carcinoma, Hepatocellular 2Xanthogranuloma, Juvenile 1Uveal Melanoma 1Uterine Neoplasms 1

Interventions

Filgrastim 20Etoposide 20Ifosfamide 19Cyclophosphamide 18Vincristine 13Radiotherapy 13Doxorubicin 13Peripheral Blood Stem Cell Transplantation 12Melphalan 12Carboplatin 10Busulfan 9Topotecan 8Temozolomide 8Magnetic Resonance Spectroscopy 8X-Rays 6Thiotepa 6Phantoms, Imaging 6Irinotecan 6Granulocyte Colony-Stimulating Factor 6Specimen Handling 5Nuclear Medicine Department, Hospital 5Biopsy 5trioctyl phosphine oxide 4Mesna 4Docetaxel 4Dactinomycin 4temsirolimus 3etoposide phosphate 3cixutumumab 3Neoadjuvant Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive, Peripheral × ulixertinib × Clear all
NCT03698994 2026-05-27

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
20 enrolled 9 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT03155620 2026-05-05

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
1,377 enrolled 10 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Xanthogranuloma, Juvenile, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡